Wave Life Sciences Q1 net loss narrows to $27.4M; cash $207.6M, pipeline advances with RNA editing candidate toward CTA

Wave Life Sciences Ltd.

2023-Q1 EPS reported -$0.27 revenue$12,929,000

Q1 revenue $12.9M from GSK/Takeda collaborations vs $1.8M a year ago; net loss $27.4M vs $37.8M.
Cash $207.6M at March 31, 2023 (up from $88.5M Dec 2022) provides runway into 2025, plus potential GSK milestones.
WVE-006, first-in-class RNA editing candidate for AATD, on track for CTA submissions in 2H 2023.
WVE-N531 for DMD: potentially registrational Phase 2 trial to start 2023 with dystrophin primary endpoint; data expected 2024.
WVE-003 HD data delayed to 2H 2023 due to cyber attack at assay vendor; no Wave data compromised.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 3, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-133192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.